Triple Chemotherapy Combination Improves Metastatic Colorectal Cancer Outcomes
- PMID: 33914943
- DOI: 10.1002/cncr.33608
Triple Chemotherapy Combination Improves Metastatic Colorectal Cancer Outcomes
Comment on
-
Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406).J Clin Oncol. 2021 Feb 1;39(4):285-294. doi: 10.1200/JCO.20.01994. Epub 2020 Dec 23. J Clin Oncol. 2021. PMID: 33356422 Free PMC article. Clinical Trial.
References
-
- Kopetz S, Guthrie KA, Morris VK, et al. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer. J Clin Oncol. 2021;39:285-294. doi:10.1200/JCO.20.01994
-
- Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med. 2019;381:1632-1643. doi:10.1056/NEJMoa1908075
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
